ZEBINIX (Maxx Pharma Pty Ltd)
Product name
ZEBINIX
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
196 (255 working days)
Active ingredients
eslicarbazepine acetate
Registration type
NCE/NBE
Indication
ZEBINIX (tablet) is indicated as:
- monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;
- adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation.